Author:
Statsenko A V,Belousova I E,Khairutdinov V R,Parfenova M A
Abstract
An up-to-date synthetic non-fluorated topical glucocorticosteroid, Histan-N (0.1% mometasone furoate cream), has an evident antiinflammatory, anti-allergic, immune-suppressive and antiproliferative action. Goal. To assess the efficacy, safety and tolerability of Histan-N for the treatment of patients with steroid-responsive dermatoses. Materials and methods. As many as 80 patients with eczema, psoriasis, atopic dermatitis, dermatitis and allergic dermatitis as well as lichen acuminatus underwent treatment. All of the patients received general pathogenetic therapy and external treatment with Histan-N. The treatment efficacy was assessed based on the trends of such dermatological indices as PASI, SCORAD and EASI as well as visual analog scale. Results. Dermatological indices reduced by 70%—90% as compared to the baseline against the background of treatment. Conclusion. The clinical results obtained for Histan-N demonstrate a substantial clinical effect of the drug, absence of adverse effects and high safety of the drug.
Publisher
Rossijskoe Obschestvo Dermatovenerologov i Kosmetologov
Reference10 articles.
1. Белоусова Т.А. Рациональное применение наружных глюкокортикостероидов в общей клинической практике. Русс мед журн 2006; (29): 2090—2094
2. Кочергин Н.Г., Новоселов В.С. Наружная терапия стероидочувствительных дерматозов: врачебный выбор. Врач 2006; (2): 42—46
3. Белоусова Т.А., Горячкина М.В. Наружные глюкокортикостероидные препараты: критерии выбора с позиции эффективности и безопасности. Вестн дерматол и венерол 2010; (6): 93—100
4. Zielinski C.E., Zuberbier T., Maurer M. Immunoregulation in cutaneous allergy: prevention and control. Curr Opin Allergy Clin Immunol 2012; 12 (5): 498—503.
5. Korting H.C., Schollmann C., Willers C., Wigger-Alberti W. Bioavailability, antipsoriatic efficacy and tolerability of a new light cream with mometasone furoate 0.1%. Skin Pharmacol Physiol 2012; 25 (3): 133—141.